NeuCen Biomedical

Executive Summary

NeuCen Biomedical is a Taiwan-based biotechnology company developing innovative nasal immunotherapy and drug delivery solutions. Leveraging its proprietary drug carrier platform, the company aims to enhance the safety and efficacy of treatments for allergic rhinitis and nasopharyngeal carcinoma. Lead candidate CEN501 is a nasal immunotherapy kit for allergic rhinitis, while NEU001 targets nasopharyngeal carcinoma. Both programs are in early-stage clinical development, with CEN501 likely in Phase 1 and NEU001 in preclinical or Phase 1. NeuCen's platform has potential for broader applications in allergy and oncology. The company is privately held and operates with a lean team of 10–50 employees.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for CEN501 in allergic rhinitis70% success
• Q4 2026IND filing or Phase 1 initiation for NEU001 in nasopharyngeal carcinoma60% success
• TBDPartnership or licensing deal for drug delivery platform40% success